PSORIATIC ARTHRITIS TREATMENT MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America has established itself as the dominant player in the global psoriatic arthritis treatment market with an estimated market share of 40.2% in 2024. With a well-developed healthcare infrastructure and high per capita healthcare expenditure, the U.S. accounts for the majority of the regional market share. Several leading pharmaceutical companies focused on rheumatology have their headquarters in the U.S., enabling strong R&D focus and rapid new product launches. Furthermore, presence of a large patient population and higher disease awareness levels have boosted demand and uptake of advanced treatment therapies. However, price controls and regulations imposed by regulatory authorities have also led to pricing pressures in the U.S. market.

Asia Pacific represents the fastest growing regional market due to  rapidly developing healthcare infrastructure across major countries like China and India. Growing medical tourism coupled with increased accessibility of treatment options drives the regional market growth. Economic growth has raised disposable incomes, allowing for higher out-of-pocket spending on specialty therapies. Presence of several contract manufacturers engaged in active pharmaceutical ingredients and drug formulation has further strengthened the Asia Pacific industry landscape. However, lack of stringent regulatory guidelines and intellectual property protection pose challenges to market growth.

European market, though well-established, still presents significant opportunities for market players. Presence of universal healthcare coverage combined with supportive government policies ensure affordable access and widespread adoption of advanced therapies. Germany, France and the U.K. collectively account for the lion's share of the region's market owing to their strong economies and focus on specialty care. Meanwhile, initiatives promoting biosimilars are exerting downward pricing pressures on innovator brands. Stringent regulations pertaining to clinical trials and product approvals delay market entry of new therapies. Regional players also face intense competition from global pharma majors headquartered outside of Europe.